Tributyrin induces growth inhibitory and differentiating effects on HT-29 colon cancer cells in vitro

International Journal of Oncology

Volumn 13, Issue 6, 1998, Pages 1335-1340

  Schröder, Claudia ^a   Eckert, Klaus ^a   Maurer, H Rainer ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Alkaline phosphatase; Carcinoembryonic antigen; Differentiation; E cadherin; HT 29 colon cancer cells; Lipofundin ; Tributyrin

Indexed keywords

ALKALINE PHOSPHATASE; BUTYRIC ACID; CARCINOEMBRYONIC ANTIGEN; TRIBUTYRIN; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL VIABILITY; COLON CANCER; COLORIMETRY; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALKALINE PHOSPHATASE; BUTYRATES; CADHERINS; CARCINOEMBRYONIC ANTIGEN; CELL DIFFERENTIATION; CELL DIVISION; GROWTH INHIBITORS; HT29 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; TRIGLYCERIDES;

EID: 0031793694     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.6.1335     Document Type: Article

References (39)

1. Bach A and Métais P: Short and medium chain fats: physiological, biochemical, nutritional and therapeutic aspects. Ann Nutr Alim 24: 75-144, 1970.
2. Drackley JK, Zhang Y, Amaral DM and Young JW: Metabolic effects of intraruminal administration of 1,3-butanediol or tributyrin in lactating goats. J Dairy Sci 72: 1986-1995, 1989.
3. Deschner EE, Ruperto JF, Lupton JR and Newmark HL: Dietary butyrate (tributyrin) does not enhance AOM-induced colon tumorigenesis. Cancer Lett 52: 79-82, 1990.
4. Wolin MJ: Fermentation in the rumen and human large intestine. Science 213: 1463-1468, 1981.
5. Cummings JH, Pomare EW, Branch WJ, Naylor CPE and Macfarlane GT: Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28: 1221-1227, 1987.
6. Roediger W: Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 21: 793-798, 1980.
7. Scheppach W, Bartram P, Richter A, Richter F, Liepold H, Dusel G, Hofstetter G, Rüthlein J and Kasper H: Effect of short-chain fatty acids on the human colonic mucosa in vitro. J Parenter Enterai Nutr 16: 43-48, 1992.
8. Prasad KN: Butyric acid: a small fatty acid with diverse biological functions. Life Sci 27: 1351-1358, 1980.
9. Kruh J: Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 42: 65-82, 1982.
10. Tsao D, Shi Z-R, Wong A and Kim YS: Effect of sodium butyrate on carcinoembryonic antigen production by human colonic adenocarcinoma cells in culture. Cancer Res 43: 1217-1222, 1983.
11. Augeron C and Laboisse CL: Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res 44: 3961-3969, 1984.
12. Chung YS, Song IS, Erickson RH, Sleisinger MH and Kim YS: Effect of growth and sodium butyrate on brush border membrane-associated hydrolases in human colorectal cancer cell lines. Cancer Res 45: 2976-2982, 1985.
13. 3. Biochem Pharmacol 38: 3859-3865, 1989.
14. Barnard JA and Warwick G: Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells. Cell Growth Differ 4: 495-501, 1993.
15. Newmark HL and Young CW: Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J Cell Biochem 22 (Suppl): 247-253, 1995.
16. Novogrodsky A, Dvir A, Ravid A, Shkolnik T, Stenzel KH, Rubin AL and Zaizov R: Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myclogenous leukemia in a child. Cancer 51: 9-14, 1983.
17. Miller AA, Kurschel E, Osieka R and Schmidt CG: Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 23: 1283-1287, 1987.
18. Velázquez OC, Jabbar A, De Matteo RP and Rombeau JL: Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice. Surgery 120: 440-448, 1996.
19. Perrin P, Cassagnau E, Burg C, Patry Y, Vavasseur F, Harb J, Le Pendu J, Douillard JY, Galmiche JP, Bornet F and Meflah K: An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. Gastroenterology 107: 1697-1708, 1994.
20. Herz F, Schermer A, Halwer M and Bogart LH: Alkaline phosphatase in HT-29, a human colon cancer cell line: influence of sodium butyrate and hyperosmolality. Arch Biochem Biophys 210: 581-591, 1981.
21. Young GP, Macrae FA, Gibson PR, Alexeyeff M and Whitehead R: Brush border hydrolases in normal and neoplastic colonic epithelium. J Gastroenterol Hepatol 7: 347-357, 1992.
22. Dorudi S, Sheffield JP, Poulsom R, Northover JMA and Hart IR: E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am J Pathol 142: 981-986, 1993.
23. Kinsella AR, Lepts GC, Hill CL and Jones M: Reduced E-cadherin expression correlates with increased invasivness in colorectal cell lines. Clin Exp Metastasis 12: 335-342, 1994.
24. Toribara NW, Sack TL, Gum JR, Ho SB, Shively JE, Willson JKV and Kim YS: Heterogeneity in the induction and expression of carcinoembryonic antigen-related antigens in human colon cancer cell lines. Cancer Res 49: 3321-3327, 1989.
25. Friedman J, Seger M, Levinsky H and Allalouf D: Modulation of carcinoembryonic antigen release by HT-29 colon carcinoma line in the presence of different asents. Experientia 43: 1121-1122, 1987.
26. Eckert K, Fuhrmann-Selter T and Maurer HR: Docetaxel enhances the expression of E-cadherin and carcinoembryonic antigen (CEA) on human colon cancer cell lines in vitro. Anticancer Res 17: 7-12, 1997.
27. Planchon P, Pouillart P, Ronco G, Villa P and Pieri F: Differential eliminination of synthetic butyric triglycerides in vivo: a pharmacokinetic study. J Pharm Sci 82: 1046-1048, 1993.
28. Conley BA, Egorin MJ, Tait N, Rosen DM, Sausville EA, Dover G, Fram RJ and van Echo DA: Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res 4: 629-634, 1998.
29. Chen ZX and Breitman TR: Tributyrin: a prodrug of butyric acid for clinical application in differentiation therapy. Cancer Res 54: 3494-3499, 1994.
30. Rocchi P, Ferreri AM, Magrini E and Perocco P: Effect of butyrate analogues on proliferation and differentiation in human neuroblastoma cell lines. Anticancer Res 18: 1099-1103, 1998.
31. Zweibaum A, Pinto M, Chevalier G, Dussaulx E, Triadou N, Lacroix B, Haffen K, Brun JL and Roussel M: Enterocytic differentiation of a subpopulation of the human colon tumor cell line HT-29 selected for growth in sugar-free medium and its inhibition by glucose. J Cell Physiol 122: 21-29, 1985.
32. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC: Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85, 1985.
33. Eckert K, Fuhrmann-Selter T, Maurer HR and Büttner P: A colorimetric imunoassay for the detection of E-cadherin and carcinoembryonic antigen (CEA) expression on human colon carcinioma cell lines in vitro. Cancer Lett 105: 1-4, 1996.
34. Reese DH, Fiorentino GJ, Claflin AJ, Malinin TI and Politano VA: Rapid induction of alkaline phosphatase activity by retinoic acid. Biochem Biophys Res Commun 102: 315-321, 1981.
35. Schauf C, Moffett D and Moffett S: Human Physiology: Foundations and Frontiers. Times Mirrow/Mosby College Publishing, St. Louis, MO, 1990.
36. Hague A, Elder DJE, Hicks DJ and Paraskeva C: Apoptosis in colorectal tumour cells: induction by the short-chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. Int J Cancer 60: 400-406, 1995.
37. Boffa LC, Gruss RJ and Allfrey VG: Manifold effects of sodium butyrate on nuclear function. J Biol Chem 256: 9612-9621, 1981.
38. Nudelman A, Ruse M, Aviram A, Rabizadeh E, Shaklai M, Zimrah Y and Rephaeli A: Novel anticancer prodrugs of butyric acid. J Med Chem 35: 687-694, 1992.
39. Pouillart P, Ceutti I, Ronco G, Villa P and Chany C: Butyric monosaccharide ester-induced cell differentiation and antitumor activity in mice. Importance of their prolonged biological effect for clinical applications in cancer therapy. Int J Cancer 49: 89-95, 1991.